Cartesian Therapeutics, Inc.
RNAC
Rank in Stocks
#18525
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Share Price
$6.11
Market Cap
$184.86M
Change (1 day)
-2.55%
Change (1 year)
815.63%
Country
US
Trade Cartesian Therapeutics, Inc. (RNAC)
Category
Healthcare
Stock split history for Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. stock (symbol: RNAC) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 19, 2026.
One RNAC share bought prior to Oct 19, 2026 would equal to 0 RNAC shares today.
The most recent stock split occurred on Oct 19, 2026.
One RNAC share bought prior to Oct 19, 2026 would equal to 0 RNAC shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
